Developer of two FDA-approved therapeutics for cardiovascular indications
CV Therapeutics was focused on the discovery, development, and commercialization of small molecule therapeutics to treat chronic cardiovascular diseases. The company gained FDA approval for two products, Ranexa (ranolazine) for angina and Lexiscan (regadenoson) for myocardial perfusion imaging. CV Therapeutics completed its IPO on NASDAQ in 1996 and was acquired by Gilead in 2009.
